跳至主要内容
临床试验/NCT05055635
NCT05055635招募中2 期

ReRad III. Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy

University of Aarhus2 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2021年7月7日最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
55
试验地点
2
主要终点
Local control

研究概览

简要总结

This protocol aims to determine toxicity and efficacy of re-irradiation for patients with recurrences from anal cancers with dose-escalated pencil beam proton therapy either pre-operative for marginally resectable recurrences or as a definitive treatment strategy (un-resectable, operation declined etc.). The over-all aim is to improve local tumor control with acceptable side effects.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Recurrent anal cancer
  • Bioptically verified (squamous cell carcinoma)
  • Available dose plan from primary radiotherapy
  • Previous RT (>30Gy EQD2)
  • Evaluated in MDT-conferences (Herlev, Aarhus)
  • Age>18 years
  • Adequate organ function
  • Written informed consent

排除标准

  • Distant metastases deemed without curative intended treatment options (PET-CT)
  • Unable to undergo MRI, PET-CT
  • Inability to attend full course radiotherapy and follow up in the outpatient clinic.

结局指标

主要结局

Local control

时间窗: 12 months

MRI

次要结局

  • Local re-recurrence(6 and 24 months)
  • Summed radiotherapy dose volume to organs at risk and correlation to toxicities(up to 6 weeks, 1 year, 3 year)
  • To investigate 30-day surgical overall morbidity(30-day)
  • Translational research(baseline, end of therapy, 1 year)
  • Quality of life assessment(up to 6 weeks, 1 year, 3 year)
  • Toxicity(up to 6 weeks, 1 year, 3 year)
  • Progression free survival(3-5 year FU)
  • Overall survival(3-5 year FU)
  • Pathological evaluation of R0, R1 or R2 resection(6 months)
  • To investigate 6-month surgical site morbidity(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验